Latest Content

Behavioral text nudges outperformed nurse calls, boosting FIT completion by 9 percentage points at an FQHC while saving staff time.

How patient experience and real-world evidence reshape hematology advances in rare disease and blood cancers, beyond clinical end points. This commentary will appear in the May issue of Evidence-Based Oncology.

The entire commercial logic of the pharmaceutical industry’s patient engagement model is built for a moment that no longer exists, according to Chris Moose.

Policy and market access experts break down the compounding forces reshaping drug pricing, PBM regulation, and manufacturer strategy heading into the 2026 midterms.

A consensus definition of high genomic complexity in chronic lymphocytic leukemia may be less important than analyzing the contributions of individual biomarkers.

A 2-week sleep/light intervention shifted teens’ circadian timing earlier, increasing weeknight sleep by about 47 minutes in a randomized trial.

A multimodal AI approach could highlight areas in the brain that were associated with cognitive worsening in patients with MS.

OCM showed no increased likelihood of starting systemic therapy in patients with newly diagnosed cancers, despite gains in poor-prognosis cases.

A case study shows positive outcomes following allogeneic stem cell transplantation in a patient with highly refractory MM and therapy-related MDS/AML.